차세대 위식도역류질환 치료제 'P-CAB', 제약 업계는 왜 P-CAB에 주목할까? - 대웅제약 뉴스룸
P-CAB 제제 대세... 미출시 '보노프라잔'도 후발약 타깃 < 제약 < 기업 < 기사본문 - 히트뉴스
Our Pipeline - Neurogastrx, Inc.
위식도역류성질환 치료제 시장, P-CAB으로 세대교체? < 제약 < 기업 < 기사본문 - 히트뉴스
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump | Journal of Medicinal Chemistry
차세대 위식도역류질환 치료제 'P-CAB', 제약 업계는 왜 P-CAB에 주목할까? - 대웅제약 뉴스룸
Potassium-competitive acid blockers and gastroesophageal reflux disease
Mode of action of P-CABs as compared with PPIs. The PPIs convert to... | Download Scientific Diagram
P-CAB agent 1 | P-CAB Agent | MedChemExpress
Study design: treatment sequences and periods for sequence PCPP and... | Download Scientific Diagram
P cab
PDF) Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
위산 관련 질환 치료를 위한 새롭고 강력한 위산분비차단제, P-CAB < 소화기/류마티스 < SH < CME < 기사본문 - 메디칼업저버
Potassium Competitive Acid Blockers (P-CAB) - GIT Pharmacology - Part 4 - YouTube
대웅제약 - 항궤양제 신약 DWP14012 / Potassium-competitive acid blocker (P-CAB) 또는 acid pump antagonist (APA) 계열
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink
PPI vs P-CAB | Treatments For Acid Reflux | Cinclus Pharma
P-CAB (Potassium-competitive acid blocker) :테고프라잔, 보노프라잔, 대웅제약 DWP14012
눈만 뜨면 희소식…점점 강해지는 P-CAB '한류' < 제약바이오 < 제약 < 기사본문 - 메디칼업저버
HK inno.N predicts global success of K-Cab based on evidence < Pharma < Article - KBR
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect
タケキャブ錠（ボノプラザン）の特徴・作用機序・副作用〜添付文書を読み解く【P-CABとPPIの違いを比較】│薬剤師の脳みそ
Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action - ScienceDirect
